Insider Trading April 9, 2026 11:49 AM

ResMed CEO Executes Options, Sells Nearly $1.12M in Shares After Q2 Beat

Michael J. Farrell exercised options and disposed of 4,991 shares as the company reported stronger-than-expected quarterly results and drew mixed analyst reactions

By Derek Hwang RMD
ResMed CEO Executes Options, Sells Nearly $1.12M in Shares After Q2 Beat
RMD

ResMed Chairman and CEO Michael J. Farrell exercised stock options to acquire 4,991 shares at $146.34 per share and sold those same shares on April 7, 2026, for a total of $1.12 million. The company posted a fiscal second-quarter EPS beat and revenue in line with expectations, prompting a range of analyst responses and price-target adjustments.

Key Points

  • ResMed CEO Michael J. Farrell exercised options for 4,991 shares at $146.34 per share and sold those 4,991 shares on April 7, 2026, for about $1.12 million, with sale prices between $222.5643 and $227.96.
  • After the transactions, Farrell directly holds 466,223 shares and indirectly holds 2,090 shares through a family trust; ResMed shares trade at $228.70 with a market capitalization of $33.15 billion.
  • ResMed reported fiscal Q2 2026 EPS of $2.81 on $1.4 billion in revenue; analysts issued mixed responses, with some raising price targets and others maintaining Hold ratings.

ResMed Inc.'s (NASDAQ: RMD) chairman and chief executive officer, Michael J. Farrell, completed a paired option exercise and share sale on April 7, 2026, according to a Form 4 filing with the Securities and Exchange Commission.

On that date Farrell exercised options to acquire 4,991 shares of ResMed common stock at an exercise price of $146.34, for a total exercise cost of $730,382. The filing shows the same 4,991 shares were sold the same day for aggregate proceeds of approximately $1.12 million, with sale prices ranging from $222.5643 to $227.96 per share.

Following the transactions, Farrell is listed as directly owning 466,223 shares of ResMed common stock. The filing also notes an indirect ownership of 2,090 shares held through the Lisette and Michael Farrell Family Trust.

At the time of reporting, ResMed stock is trading at $228.70, which corresponds to a market capitalization of $33.15 billion.


Company results and analyst responses

ResMed reported fiscal second-quarter 2026 results that included earnings per share of $2.81, beating analyst forecasts of $2.73. Revenue for the quarter was reported at $1.4 billion, which met consensus expectations. The company recorded double-digit revenue and earnings growth as described by one investment bank.

Analyst reactions following the quarterly results were varied but generally constructive. One firm raised its price target to $314 from $311 and maintained an Outperform rating. Another raised its target to $302 from $299 and kept an Overweight rating, citing a solid revenue beat. Other firms maintained more cautious stances - one reiterated a Hold rating while noting an improvement in organic revenue growth to 8% in the second quarter, up from 7% in the prior quarter; another also maintained a Hold rating with a $265 price target.


Valuation commentary and dividend history

Separately, an analysis noted in market commentary suggested the stock is undervalued relative to its Fair Value. That commentary also referenced ResMed's track record of consecutive dividend increases, stating the company has raised its dividend for 14 straight years. The commentary indicated there are additional proprietary tips and deeper research available through subscription research resources.


Context and implications

The filings and company results together provide a picture of active insider liquidity occurring simultaneously with a quarterly performance that exceeded EPS estimates and matched revenue expectations. The combination of executive transactions, public financial results, and subsequent analyst updates gives investors multiple data points to consider when assessing the stock.

All transaction details are drawn from the Form 4 filing referenced above and the company-reported quarterly results and publicly disclosed analyst reactions.

Risks

  • Divergent analyst ratings and price targets indicate differing expectations for future performance, creating uncertainty for investors considering valuation and near-term upside - this affects equity investors and the medical device sector.
  • Insider option exercises and same-day share sales change insider ownership levels and may be interpreted in multiple ways by market participants, introducing potential sentiment-driven volatility in ResMed shares - relevant to investors in healthcare equipment stocks.
  • Discrepancies between proprietary fair-value assessments and current market price create valuation uncertainty for shareholders and prospective buyers - impacting portfolio managers and analysts focused on healthcare and medical-device equities.

More from Insider Trading

JFB Construction Director Disposes of Nearly $60,000 in Shares; Company Reports Revenue Gain and Drone Subsidiary Milestones Apr 9, 2026 Horizon Kinetics Makes Minimal Purchase of Texas Pacific Land Share at $447.12 Apr 9, 2026 Teradyne Executive Sells Small Stake as Company Nears 52-Week High Apr 9, 2026 Nordson Executive Sells $197,487 in Stock as Analysts Adjust Targets After Q1 Results Apr 9, 2026 Prosperity Bancshares Director Sells $75,877 in Stock; Ownership Stakes Left Largely Intact Apr 9, 2026